Celgene Sues Hikma To Block Revlimid Generic
Celgene has hit Hikma Pharmaceuticals USA Inc. with a lawsuit in New Jersey federal court seeking to block Hikma from marketing generic versions of the Bristol-Myers Squibb unit's cancer drug Revlimid....To view the full article, register now.
Already a subscriber? Click here to view full article